produce high amounts of algal β-1,3-glucan, which evoke an immune response when consumed. This study investigated the effect of supplementation with a proprietary fermentate (BG), containing greater than 50% β-1,3-glucan, on immune function as measured by self-reported changes in upper respiratory tract infection (URTI) symptoms. Thirty-four healthy, endurance-trained participants were randomized and received either 367 mg of BG or placebo (PLA) for 90 days. Symptoms were assessed by the 24-item Wisconsin Upper Respiratory Symptom Survey and safety via clinical chemistry, hematology, vitals, and adverse event reporting. Participants supplemented with BG over 90 days reported fewer sick days (BG: 1.46 ± 1.01; PLA: 4.79 ± 1.47 days; = 0.041), fewer URTI symptoms (BG: 12.62 ± 5.92; PLA: 42.29 ± 13.17; = 0.029), fewer symptom days (BG: 5.46 ± 1.89; PLA: 15.43 ± 4.59 days; = 0.019), fewer episodes (BG: 2.62 ± 0.67; PLA: 4.79 ± 0.67; = 0.032), and lower global severity measured as area under curve for URTI symptoms (BG: 17.50 ± 8.41; PLA: 89.79 ± 38.92; = 0.0499) per person compared to placebo. Sick days, symptoms, and global severity were significantly ( < 0.05) fewer over 30 days in the BG group compared to PLA. All safety outcomes were within clinically normal ranges. The study provides evidence that supplementation with a proprietary fermentate containing greater than 50% β-1,3-glucan may reduce and prevent URTI symptoms, providing immune support and protecting overall health.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950611 | PMC |
http://dx.doi.org/10.3390/nu11122926 | DOI Listing |
Int J Mol Sci
December 2024
3P-Medicine Laboratory, Medical University of Gdańsk, Dębinki Street 7, 80-211 Gdańsk, Poland.
Upper respiratory tract infections (URTIs) are a prevalent health issue, causing considerable morbidity. Despite the availability of conventional treatments, there is an increasing interest in natural products due to their potential antiviral and immunomodulatory benefits. This study aims to evaluate the efficacy of an ELA blend (E-, L-, A-) in preventing and alleviating the symptoms of URTIs.
View Article and Find Full Text PDFClin Pharmacol Drug Dev
January 2025
Department of Pediatrics, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Dexibuprofen is the pharmacologically active enantiomer of ibuprofen. However, its application as an antipyretic in children with fever caused by upper respiratory tract infection (URTI) requires more evidence. This study aimed to compare the antipyretic effect between dexibuprofen and ibuprofen in children with fever caused by URTI.
View Article and Find Full Text PDFPLoS One
December 2024
Centre for Health Informatics, Faculty of Biology, Medicine and Health, School of Health Sciences, the University of Manchester, Manchester, United Kingdom.
Background: Antimicrobial resistance (AMR) is a multifaceted global challenge, partly driven by inappropriate antibiotic prescribing. The objectives of this study were to evaluate the impact of the COVID-19 pandemic on treatment of common infections, develop risk prediction models and examine the effects of antibiotics on infection-related hospital admissions.
Methods: With the approval of NHS England, we accessed electronic health records from The Phoenix Partnership (TPP) through OpenSAFELY platform.
Immunol Res
December 2024
Disciplina de Imunologia Clínica, Faculdade de Medicina, Centro Universitário FMABC, Avenida Lauro Gomes, 2000, Santo Andre, SP, 09060.870, Brazil.
Selective IgM deficiency (SIgMD) has recently been included in the inborn errors of immunity classification. SIgMD has conflicting diagnostic criteria and diverse clinical and immunological findings. We aimed to assess the clinical and laboratory profiles of patients with SIgMD and to compare the data of patients diagnosed using two inclusion criteria.
View Article and Find Full Text PDFCureus
December 2024
Family Medicine, USF Gualtar, Unidade Local de Saúde de Braga, Braga, PRT.
Acute upper respiratory tract infections (URTIs) are defined as infectious diseases confined anatomically to the upper respiratory tract, with a duration of up to 28 days. Treatment for URTIs in pediatrics typically involves antipyretics and decongestants and, at times, antibiotics, despite most infections being viral. Nasal irrigation with saline solution is frequently used as an adjunct treatment for URTI symptoms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!